SANTARELLI

What are you looking for?

Enter at least 2 characters.

Esc to close

In its order of 22 October 2026, the Milan Central Division of the Unified Patent Court (UPC) addressed this question in Sandoz v Novo Nordisk (UPC_CFI_2221/2026).

Sandoz sought revocation of Novo Nordisk’s unitary patent EP3689365 (EP’365), covering once-weekly semaglutide treatment for type 2 diabetes. Parallel EPO opposition proceedings were also pending.

Sandoz also sought to prevent a potential “divisional game”. With another application in the same patent family (EP4406593), still pending, Sandoz feared Novo Nordisk could withdraw EP’365 to avoid an adverse validity ruling while pursuing equivalent protection through divisionals, a strategy described as the “divisional game”.

Beyond revocation, Sandoz submitted three additional requests. The Court ruled as follows:

1. A declaration that the semaglutide composition and dosing regimen were obvious at the patent’s priority date → Rejected

The Court found the request too abstract, as it was not linked to a specific patent right or identified Sandoz product or activity and could affect third-party rights. The Court distinguished this from a UK Arrow declaration, which seeks to establish that a defined product or process was already known or obvious at a given date, helping clear the way against future patent claims.

2. A declaration that claims in the same patent family covering EP’365’s subject-matter would lack of inventive step → Jurisdiction confirmed

The Court considered this Arrow-type relief, while leaving questions of admissibility and merits for later. Crucially, the Court identified another route: under Rule 360 RoP, patent withdrawal does not automatically end UPC revocation proceedings. If an abusive divisional strategy threatens judicial review, the UPC may continue the action and rule on validity despite withdrawal. Such a ruling could be relevant to later proceedings involving substantially corresponding divisional claims, but would not automatically invalidate them; third-party rights must be respected.

3. An order preventing Novo Nordisk from withdrawing its approval of the patent text before the EPO → Jurisdiction confirmed

The Court recognized its power to grant such a measure, subject to urgency, necessity and proportionality and the balance of interests. No order was granted.

Key takeaway: For patent proprietors, patent withdrawal may not automatically end UPC revocation proceedings. For third parties, a validity ruling may still be useful after patent withdrawal, as it could be relied upon in later infringement or revocation proceedings involving substantially equivalent divisional claims. Its effects would require a case-by-case assessment.

Importantly, no abuse or invalidity was established; no Arrow-type declaration or protective order was granted. The Court granted leave to appeal, meaning further developments may follow.

Nawhel GUILLAUMEY, Ingénieure Brevets chez Santarelli, cabinet de propriété intellectuelle.

Nawhel Guillaumey
Patent Attorney

Trademark

Maldives: a new trademark registration system in 2026, finally open to all applicants

Trademark

Domain Name Update: “.BRAND” Extensions (i.e., your brand or company name)

Patent

Color and Grayscale Drawings Now Accepted by the EPO